Current Oncology Reports

, Volume 3, Issue 5, pp 396–403

Economic analysis of randomized, controlled trials

  • Gary H. Lyman
Article

Abstract

To facilitate the comparison of different treatment strategies, measures have been developed that bring together clinical, quality-of-life, and economic outcomes into summary measures such as the quality-adjusted life year, cost-effectiveness, and cost-utility ratios. A number of different types of economic evaluations have been developed, including cost-minimization, cost-effectiveness, and cost-utility analyses. Performance of economic analyses in association with randomized, controlled trials (RCT) has gained increasing enthusiasm in recent years. However, economic measures in RCTs are often outcomes of secondary interest and associated with frequent missing data and inadequate sample size. Variability in the cost measures used and the lack of agreement on clinically meaningful cost differences further limit the conclusions derived from such studies. Economic analyses should be limited to large trials with important trade-offs between efficacy and cost. The strengths and limitations of such analyses are discussed, and guidelines are offered for proper economic analyses in randomized, controlled trials.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Brown ML: The national economic burden of cancer: an update. J Natl Cancer Inst 1990, 82:1811–1814.PubMedCrossRefGoogle Scholar
  2. 2.
    Brown ML, Fintor L: The economic burden of cancer. In Cancer Prevention and Control. Edited by Greenwald P, Kramer BS, Weed, DC. New York: Marcel Dekker; 1995:1–12.Google Scholar
  3. 3.
    Gaumer GL, Stavins J: Medicare use in the last 90 days of life. Med Care 1991, 29:725–742.Google Scholar
  4. 4.
    Baker MS, Kessler LC: Site-specific treatment costs In. In Cancer Care and Cost. Edited by Scheffler RM, Andews NC. Chicago: Health Administration Press; 1989.Google Scholar
  5. 5.
    Wright JC, Weinstein MC: Gains in life expectancy from medical interventions: standardizing data on outcomes. N Engl J Med 1998, 330:380–404.CrossRefGoogle Scholar
  6. 6.
    Cella DF, Bonomi AE: Measuring quality of life: 1995 update. Oncology 1995, 9:47–60. Summary of psychometric patient profile measures as exemplified by the Functional Assessment of Cancer Treatment (FACT) scales developed by Cella et al.PubMedGoogle Scholar
  7. 7.
    Weeks J: Measurement of utilities and quality-adjusted survival. Oncology 1995, 9:67–70.PubMedGoogle Scholar
  8. 8.
    Gelber RD, Goldhirsch A, Cavelli F: Quality-of-life-adjusted evaluation of adjuvant therapy for operable breast cancer. Ann Int Med 1991, 114:621–628. This important paper addresses the cumulative impact of patient preferences over time, expressed as quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWiST), enhancing the power to demonstrate an impact of treatment on patient quality of life.PubMedGoogle Scholar
  9. 9.
    Gotay CC, Korn EL, McCabe MS, et al.: Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 1992, 84:575–579.PubMedCrossRefGoogle Scholar
  10. 10.
    Drummond MF: Resource allocation decisions in health care: a role for quality of life assessments. J Chron Dis 1987, 40:605–616.PubMedCrossRefGoogle Scholar
  11. 11.
    Staquet MJ, Hays RD, Fayers PM: Quality of Life Assessment in Clinical Trials: Methods and Practice. Oxford: Oxford University Press; 1998.Google Scholar
  12. 12.
    Olschewski M, Schulgen G, Schumacher M, Altman DG: Quality of life assessment in clinical cancer research. Br J Cancer 1994, 70:1–5.PubMedGoogle Scholar
  13. 13.
    Pocock SJ: A perspective on the role of quality-of-life assessment in clinical trials. Controlled Clinical Trials 1991, 12:257S-265S.PubMedCrossRefGoogle Scholar
  14. 14.
    Fayers PM, Hopwood P, Harvey A, et al.: Quality of life assessment in clinical trials: guidelines and a checklist for protocol writers. The UK Medical Research Council Experience. Eur J Cancer 1997, 33:20–28.PubMedCrossRefGoogle Scholar
  15. 15.
    Detsky AS, Naglie IG: A clinician’s guide to cost-effectiveness analysis. Ann Int Med 1990, 113:147–154.PubMedGoogle Scholar
  16. 16.
    Task Force on Principles for Economic Analyses of Health Care Technology: Economic analyses of health care technology: a report on principles. Ann Int Med 1995, 122:61–70.Google Scholar
  17. 17.
    American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996, 14:671–679.Google Scholar
  18. 18.
    Russell LB, Gold MR, Siegel JE, et al.: The role of costeffectiveness analysis in health and medicine. JAMA 1996, 276:1172–1177.PubMedCrossRefGoogle Scholar
  19. 19.
    Weinstein MC, Siegel JE, Gold MR, et al.: Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996, 276:1253–1258. See annotation for [20••].PubMedCrossRefGoogle Scholar
  20. 20.
    Siegel JE, Weinstein MC, Russell LB, Gold MR: Recommendations for reporting cost-effectiveness analysis. JAMA 1996, 276:1330–1341. Landmark companion papers representing a comprehensive effort to define the role of economic analysis in health care and provide guidelines for the conduct and reporting of such analyses in the medical literature.CrossRefGoogle Scholar
  21. 21.
    Udvarhelyi IS, Colditz GA, Rai A, Epstein AM: Cost effectiveness and cost benefit analyses in the medical literature: are the methods being used correctly? Ann Int Med 1992, 116:238–244.PubMedGoogle Scholar
  22. 22.
    Drummond MF, Davies L: Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7:561–573.PubMedGoogle Scholar
  23. 23.
    Drummond MF, Stoddart GL: Economic analysis and clinical trials. Controlled Clinical Trials 1984, 5:115–128. A pivotal paper by one of the pioneers and leading authorities in defining the role of economic analyses in association with controlled clinical trials. Most of the major strengths and weaknesses associated with such studies are discussed.PubMedCrossRefGoogle Scholar
  24. 24.
    Bennett CL, Golub R, Waters TM, et al.: Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest 1997, 15:227–236.PubMedGoogle Scholar
  25. 25.
    Bennett CL, Armitage JL, Buchner D, Gulati S: Economic analysis in phase III clinical cancer trials. Cancer Invest 1994, 12:336–342.PubMedGoogle Scholar
  26. 26.
    Bennett CL, Westerman IL: Economic analysis during phase III clinical trials: who, what, when where, and why? Oncology 1995, 9:169–175.PubMedGoogle Scholar
  27. 27.
    Brown M, Glick HA, Harrell F, et al.: Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology economics workbook. J Natl Cancer Inst Monogr 1998, 24:1–28. Excellent overview of the second national conference on the design and analysis of economic analyses in association with controlled clinical trials. Participants included clinicians, statisticians, and economists as well as representatives of the major national cancer cooperative groups, the National Cancer Institute, and the American Society of Clinical Oncology.Google Scholar
  28. 28.
    Coyle D, Davies LK, Drummond MF: Trials and tribulations: emerging issues in designing economic evaluations alongside clinical trials. Int J Technol Assess Health Care 1998, 14:135–144.PubMedCrossRefGoogle Scholar
  29. 29.
    O’Brien BJ, Drummond MF, Labelle RJ, Willan A: In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994, 32:150–163.PubMedCrossRefGoogle Scholar
  30. 30.
    Rutten-Van Mölken MPMH, Van Doorslaer EKA, Van Vliet RCJA: Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Econ 1994, 3:333–345.PubMedCrossRefGoogle Scholar
  31. 31.
    Grieve AP: Issues for statisticians in pharmaco-economic evaluations. Stat Med 1998, 17:1715–1723.PubMedCrossRefGoogle Scholar
  32. 32.
    Barber JA, Thompson SG: Analysis and interpretation of cost data in randomized controlled trials: review of published studies. Brit Med J 1998; 317:1195–1200.PubMedGoogle Scholar
  33. 33.
    Zhou XH, Gao S: Confidence intervals for log-normal means. Stat Med 1997; 16:783–790.PubMedCrossRefGoogle Scholar
  34. 34.
    Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457–481.CrossRefGoogle Scholar
  35. 35.
    Heitjan DF, Moskowitz AJ, Whang W: Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ 1999; 8:191–201.PubMedCrossRefGoogle Scholar
  36. 36.
    Balas EA, Rainer ACK, Gnann W, et al.: Interpreting cost analysis of clinical interventions. JAMA 1998, 279:54–57.PubMedCrossRefGoogle Scholar
  37. 37.
    Drummond MF, Jefferson TO, on behalf of the BMJ Economic Evaluation Working Party: Guidelines for authors and peer reviewers of economic submissions to the B.J. BMJ 1996, 313:275–283.PubMedGoogle Scholar
  38. 38.
    Fayers PM, Hand DJ: Generalization from phase III clinical trials: survival, quality of life, and health economics. Lancet 1997, 350:1025–1027.PubMedCrossRefGoogle Scholar
  39. 39.
    Earle CC, Coyle D, Evans WK: Cost-effectiveness analysis in oncology. Ann Oncol 1998, 9:475–482.PubMedCrossRefGoogle Scholar
  40. 40.
    Smith TJ, Hillner BE, Desch CE: Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993, 85:1460–1474. Comprehensive compilation of efficacy and cost-effectiveness studies in oncology based on decision analysis methods.PubMedCrossRefGoogle Scholar
  41. 41.
    Smith TJ, Hillner BE: The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in pre-menopausal women. J Clin Oncol 1993, 11:771–776.PubMedGoogle Scholar
  42. 42.
    Reeves GAG: Cost effectiveness in oncology. Lancet 1985, 2:1405–1408.CrossRefGoogle Scholar
  43. 43.
    Goodwin PJ, Feld R, Evans WK, Pater J: Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 1988, 6:1537–1547.PubMedGoogle Scholar
  44. 44.
    Smith TJ, Hillner BE, Neighbors DM, et al.: Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol 1995, 13:2166–2173.PubMedGoogle Scholar
  45. 45.
    Jaakkimainen L, Goodman PJ, Pater J, et al.: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial of non-small cell lung cancer. J Clin Oncol 1990, 8:1301–1309.PubMedGoogle Scholar
  46. 46.
    Hillner BE, Smith TJ, Desch CE: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analysis while awaiting clinical trial results. JAMA 1992, 267:2055–2061.PubMedCrossRefGoogle Scholar
  47. 47.
    Emanuel EJ, Emanuel LL: The economics of dying: the illusion of cost savings at the end of life. N Engl J Med 1994, 330:540–544.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Gary H. Lyman
    • 1
  1. 1.Albany Medical CenterAlbanyUSA

Personalised recommendations